The following new studies are now open in Kingston Hospital’s Research and Innovation department:
Poetic study (Pre-Operative Endocrine Therapy for Individualised Care with Abemaciclib):
The main aim of this study is to determine the benefit of adding the drug ‘Abemaciclib’ to endocrine therapy in breast cancer patients who are exhibiting early evidence of sub-optimal endocrine responsiveness and a high risk of disease relapse.
The Institute of Cancer Research (ICR) is the study sponsor, with Professor Stephen Johnston as the Chief Investigator. The study is funded by Lilly and Cancer Research UK (via ICR Clinical Trials and Statistics Unit (ICR-CTSU) programme). ICR-CTSU is responsible for the central co-ordination of the trial, on behalf of the sponsor.
COPE study (Carboprost or Oxytocin Postpartum haemorrhage Effectiveness):
The COPE study aims to compare carboprost with oxytocin as initial treatments for women with clinically diagnosed Postpartum Haemorrhage (PPH) after giving birth in UK hospitals. The study will assess the relative cost-effectiveness of the use of carboprost and oxytocin as initial treatments for women with clinically diagnosed PPH and will explore the views of participants and their carers about their experiences of the two treatments and the consent process.
The University of Liverpool is responsible for managing this study as the sponsor, with Prof Andrew Weeks as the Chief Investigator. The Liverpool Clinical Trials Centre has the overall management responsibility for the trial and responsibility for the co-ordination of centres. This study is funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme.